Meeting
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
Authors
Seunghwan Shin
Oncology, Lunit, Seoul, Korea, Republic of (South)
Seunghwan Shin , Soo Youn Cho , Eun Yoon Cho , So-Woon Kim , Minsun Jung , Seung-Geun Song , Yoojoo Lim , Soo Ick Cho , Sukjun Kim , Gahee Park , Heon Song , Minuk Ma , Donggeun Yoo , Chan-Young Ock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1049)
DOI
10.1200/JCO.2023.41.16_suppl.1049
Abstract #
1049
Poster Bd #
270
Abstract Disclosures
Similar Posters
First Author: Natália Polidorio
Poster
2017 ASCO Annual Meeting
Survival by HER2 receptor status in stage IV breast cancer: SEER 2010-2012.
First Author: Alexandra Thomas
Poster
2024 ASCO Annual Meeting
Multilevel factors associated with delays to neoadjuvant chemotherapy among young adults with operable breast cancer.
First Author: Melissa Beauchemin
Poster
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
First Author: Joshua Z. Drago